BioSpace News Archive

Zimmer Biomet Holdings, Inc., a global medical technology leader, introduced the availability of new artificial intelligence¹ capabilities within Omni™ Suite, an intelligent operating room designed to optimize surgical workflow and procedural efficiency by automating manual tasks and streamlining unnecessary technology and redundant hardware.

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Dr. Matt Coffey, President and Chief Executive Officer, will participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference.

Zynex, Inc. announced that it will participate in two upcoming investor conferences.

Compugen Ltd. announced that Mr. Ari Krashin, Chief Financial Officer and Chief Operating Officer of Compugen Ltd., notified the Company of his wish to depart from his position at the Company to pursue other interests.

Karyopharm Therapeutics Inc. announced that the Company’s senior management team will participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference on Tuesday, May 17, 2022 at 4:35 p.m. ET in New York, NY.

Panag Pharma Inc (Panag), a subsidiary of Tetra Bio-Pharma, will collect royalties on sales on products produced with the technology True North has licensed from Panag.

Bruker Corporation and TOFWERK AG today announced a strategic partnership for high-speed, ultra-sensitive applied and industrial analytical solutions, in conjunction with a Bruker minority investment in TOFWERK.

Castle Biosciences, Inc. today announced that for the second year, it is a national sponsor of The Sun Bus, a mobile clinic that provides free skin checks and sun safety education across numerous U.S. states.

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the first quarter of 2022 and provided business updates.

Seres Therapeutics to Present Data on Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting.